Clinical Trial Update: Assessment of Chronic Guillain-Barre Syndrome Improvement With Use of 4-aminopyridine [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the effectiveness of 4-aminopyridine for improving symptoms in chronic Guillain-Barré syndrome has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Guillain-barré Syndrome

Drugs mentioned

• 4-aminopyridine (4-aminopyridine)

Snippet

Sponsor: FDA Office of Orphan Products Development | Conditions: Guillain-Barre Syndrome | Phase 2 | Status: COMPLETED